In Vivo Efficacy of SQ109 against Leishmania donovani, Trypanosoma spp. and Toxoplasma gondii and In Vitro Activity of SQ109 Metabolites

SQ109 is an anti-tubercular drug candidate that has completed Phase IIb/III clinical trials for tuberculosis and has also been shown to exhibit potent in vitro efficacy against protozoan parasites including Leishmania and Trypanosoma cruzi spp. However, its in vivo efficacy against protozoa has not...

Descripción completa

Detalles Bibliográficos
Autores principales: Baek, Kyung-Hwa, Phan, Trong-Nhat, Malwal, Satish R., Lee, Hyeryon, Li, Zhu-Hong, Moreno, Silvia N. J., Oldfield, Eric, No, Joo Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944987/
https://www.ncbi.nlm.nih.gov/pubmed/35327472
http://dx.doi.org/10.3390/biomedicines10030670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944987/
https://www.ncbi.nlm.nih.gov/pubmed/35327472
http://dx.doi.org/10.3390/biomedicines10030670

Ejemplares similares